Friday | ||||
Conference/Events
|
Amyris to host conference call »
16:24 04/16/21 04/1616:24 04/16/2116:24
AMRS
Amyris
Management holds an… Management holds an investor update conference call on April 22 at 1 pm. Webcast Link ShowHide Related Items >><<
|
Thursday | ||||
Hot Stocks
|
Amyris to acquire EcoFabulous Cosmetics, terms not disclosed »
08:03 04/15/21 04/1508:03 04/15/2108:03
AMRS
Amyris
Amyris announced that it… Amyris announced that it has executed a binding term sheet for the acquisition of Gen Z-focused beauty brand, EcoFabulous Cosmetics. The acquisition furthers Amyris's growth and market leadership in clean beauty and complements Amyris's family of consumer brands, consisting of Biossance, Pipette, Rose Inc., JVN, Terasana, and Costa Brazil. Amyris is acquiring a 70% controlling interest in EcoFabulous and expects to grow the Gen Z consumer segment through Amyris's innovative science, sustainable ingredients, clean formulation and direct-to-consumer marketing expertise. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand. ShowHide Related Items >><<
|
Wednesday | ||||
Hot Stocks
|
Amyris to acquire Beauty Labs, terms not disclosed »
08:02 04/14/21 04/1408:02 04/14/2108:02
AMRS
Amyris
Amyris announced that it… Amyris announced that it has agreed to acquire Beauty Labs, an AI technology company that provides connected consumer experiences to the beauty and wellness community. The parties expect to sign a definitive agreement and close over the next 30 days subject to the successful completion of due diligence and customary closing conditions. ShowHide Related Items >><<
|
Over a week ago | ||||
Syndicate
|
Amyris 19.05M share Spot Secondary priced at $15.75 »
06:13 04/09/21 04/0906:13 04/09/2106:13
AMRS
Amyris
The deal size was… The deal size was increased to $300M from $250M and priced below the last closing price of $16.04. JPMorgan and Cowen are acting as joint book running managers for the offering. ShowHide Related Items >><<
| |||
On The Fly
|
Fly Intel: Pre-market Movers »
08:59 04/08/21 04/0808:59 04/08/2108:59
ORBC
Orbcomm
Immutep
GameStop
AVCtechnologies
Conagra Brands
Apogee Enterprises
Valero
Box
Otonomy
Amyris
Canopy Growth
Check out this morning's… ShowHide Related Items >><<
|
On The Fly
|
Fly Intel: After-Hours Movers »
18:56 04/07/21 04/0718:56 04/07/2118:56
RGP
Resources Connection
AVCtechnologies
Landec
Chinook Therapeutics
Amyris
Otonomy
Progress Software
Check out this evening's… ShowHide Related Items >><<
|
Hot Stocks
|
Amyris drops 7% to $15.60 after announcing $250M common stock offering
17:59 04/07/21 04/0717:59 04/07/2117:59
AMRS
Amyris
ShowHide Related Items >><<
|
Syndicate
|
Amyris announces $250M offering of common stock »
17:49 04/07/21 04/0717:49 04/07/2117:49
AMRS
Amyris
Amyris is conducting a… Amyris is conducting a resale of stock on behalf of its current stockholders, DSM International B.V. and affiliates of Vivo Capital LLC. The selling stockholders intend to offer an aggregate of $150M of shares of Amyris's common stock. Amyris will not receive any proceeds from the sale of the shares by the selling stockholders. Additionally, Amyris intends to offer $100M of shares of its common stock to support its continued growth. J.P. Morgan Securities and Cowen and Company are acting as the joint bookrunning managers for the proposed offering. ShowHide Related Items >><<
|
Syndicate
|
Amyris files automatic mixed securities shelf
17:20 04/07/21 04/0717:20 04/07/2117:20
AMRS
Amyris
ShowHide Related Items >><<
|
Hot Stocks
|
Amyris signs supply agreement with DSM Nutritional Products »
08:09 03/31/21 03/3108:09 03/31/2108:09
AMRS
Amyris
Amyris announced that it… Amyris announced that it has signed and closed an agreement with DSM Nutritional Products for the exclusive rights to supply Amyris's product portfolio of flavor and fragrance ingredients. Amyris will continue to develop, scale and manufacture future molecules with its existing partners and DSM. The total transaction value is estimated at over $500M from short and long-term contributions with approximately 1/3 as an upfront payment at closing, more than 1/3 from potential earn-out payments based on milestones over the three year period from 2022 through 2024, and the remainder attributable to a 15-year manufacturing agreement between Amyris and DSM and the expected value of developing and scaling a pipeline of new F&F molecules through collaboration agreements. ShowHide Related Items >><<
|